^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...Metastatic or unresectable disease…Combination targeted therapy and immunotherapy if BRAF V600-activating mutation present…Dabrafenib/trametinib + pembrolizumab
